Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with ...

PARMA, Italy, March 30, 2026 (GLOBE NEWSWIRE)-- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...

Evinacumab is highlighted as a new therapy for treating patients with homozygous FH. Eliot Brinton, MD: There has been a recent breakthrough in HoFH [homozygous familial hypercholesterolemia] ...

Review the side-effects of Lomitapide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 to recommend approval of Aegerion Pharmaceuticals' cholesterol-lowering drug lomitapide for use in patients with homozygous ...

The FDA has approved lomitapide (Aegerion Pharmaceuticals, Cambridge, MA) as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL-C, total ...

Cambridge, MA - Aegerion Pharmaceuticals says it is preparing regulatory filings in the US and Europe for its "orphan" drug lomitapide, a small-molecule microsomal triglyceride transfer protein ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...